Granted Patent
B2
US 12,303,487 · App. 17/295,405 · Granted May 20, 2025
N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
Assignee:
Spoke Sciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The current disclosure provides use of N-acylated fatty amino acids to reduce absorption variability in cannabinoid-based compositions.
Claims (19)
1. A method of reducing cannabinoid blood absorption inter-subject variability, the method comprising:
administering to a plurality of subjects an oral formulation comprising a cannabinoid with an aqueous solubility of less than 0.1 mg/ml selected from:
Δ9-Tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinol propyl variant (CBNV), cannabitriol (CBO), and/or mixtures thereof;
and an N-acylated fatty amino acid or salt thereof having a formula:
wherein X is sodium or potassium, and Z is hydrogen,
wherein the weight/weight (w/w) ratio of cannabinoid/N-acylated fatty amino acid or salt thereof within the oral formulation is 1:6 or 1:10;
thereby reducing the cannabinoid blood absorption inter-subject variability,
wherein the reduced cannabinoid blood absorption inter-subject variability is evidenced by a coefficient of variation (% CV) of area under a plasma concentration-time curve that is less than 50%.
2. The method of claim 1 , wherein the oral formulation comprising the cannabinoid and the N-acylated fatty amino acid or salt thereof comprises a powder or an oral solution.
3. The method of claim 1 , wherein the oral formulation comprises
50 mg cannabidiol (CBD) and 300 mg N-acylated fatty amino acid or salt thereof;
10 mg Δ9-Tetrahydrocannabinol (THC) and 100 mg N-acylated fatty amino acid or salt thereof;
50 mg CBD and 500 mg N-acylated fatty amino acid or salt thereof; or
30 mg CBD and 300 mg N-acylated fatty amino acid or salt thereof.
4. The method of claim 1 , wherein the cannabinoid comprises cannabidiol (CBD).
5. The method of claim 1 , the N-acylated fatty amino acid or salt thereof comprises sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).
6. The method of claim 1 , wherein the oral formulation comprises a gelatin capsule.
7. The method of claim 1 , wherein the oral formulation further comprises flavonoid compounds, terpenes, or terpenoids.
8. The method of claim 2 , wherein the powder is formed by wet granulation.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 1, 2023
From: RECEPTOR HOLDINGS INC.
To: SPOKE SCIENCES, INC
Reel/Frame 065427/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 1, 2021
From: LEONE-BAY, ANDREA; WESNER, GREGORY
To: RECEPTOR LIFE SCIENCES, INC.
Reel/Frame 056405/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 1, 2021
From: LEONE-BAY, ANDREA; WESNER, GREGORY
To: RECEPTOR HOLDINGS INC.
Reel/Frame 056405/0158 →
CHANGE OF NAME
Recorded Jun 1, 2021
From: RECEPTOR LIFE SCIENCES, INC.
To: RECEPTOR HOLDINGS, INC.
Reel/Frame 056447/0827 →
Continuity (2)
Provisional Application
62769395
· Nov 19, 2018
References Cited (245)
US 2385365A
· Link
· 1945
[cited by applicant]
US 3939259A
· Pescetti
· 1976
[cited by applicant]
US 4124549A
· Hashiudo et al.
· 1978
[cited by applicant]
US 4374082A
· Hochschild
· 1983
[cited by applicant]
US 4758597A
· Martin et al.
· 1988
[cited by applicant]
US 4902513A
· Carvais
· 1990
[cited by applicant]
US 5215754A
· Valorose et al.
· 1993
[cited by applicant]
US 5650386A
· Leone-Bay et al.
· 1997
[cited by applicant]
US 5866536A
· Leone-Bay et al.
· 1999
[cited by applicant]
US 5965162A
· Fuisz et al.
· 1999
[cited by applicant]
US 6495177B1
· deVries et al.
· 2002
[cited by applicant]
US 7745488B2
· Gagnon et al.
· 2010
[cited by applicant]
US 8022048B2
· Castelli et al.
· 2011
[cited by applicant]
US 8513300B2
· Abbas et al.
· 2013
[cited by applicant]
US 9125833B2
· Babul
· 2015
[cited by applicant]
US 9186412B2
· Kidron et al.
· 2015
[cited by applicant]
US 20020065255A1
· Bay et al.
· 2002
[cited by applicant]
US 20030191069A1
· Inaba
· 2003
[cited by applicant]
US 20040161819A1
· Aharoni et al.
· 2004
[cited by applicant]
US 20040224020A1
· Schoenhard
· 2004
[cited by applicant]
US 20050244490A1
· Otto et al.
· 2005
[cited by applicant]
US 20060293354A1
· Eatherton
· 2006
[cited by applicant]
US 20070072939A1
· Kupper
· 2007
[cited by applicant]
US 20080063711A1
· Grenier et al.
· 2008
[cited by applicant]
US 20080103139A1
· Ishizuka
· 2008
[cited by applicant]
US 20080194676A1
· Abbas et al.
· 2008
[cited by applicant]
US 20090155392A1
· Nelson et al.
· 2009
[cited by applicant]
US 20100068297A1
· Naughton
· 2010
[cited by applicant]
US 20100168066A1
· Muehlebach
· 2010
[cited by applicant]
US 20110092583A1
· Murty et al.
· 2011
[cited by applicant]
US 20110137040A1
· Lange
· 2011
[cited by applicant]
US 20120237570A1
· Crain et al.
· 2012
[cited by applicant]
US 20130040910A1
· Castelli et al.
· 2013
[cited by applicant]
US 20130224300A1
· Maggio
· 2013
[cited by applicant]
US 20130295026A1
· Viernstein et al.
· 2013
[cited by applicant]
US 20140154317A1
· Al-Mehdar
· 2014
[cited by applicant]
US 20140193345A1
· Levine et al.
· 2014
[cited by applicant]
US 20140209109A1
· Larson
· 2014
[cited by applicant]
US 20140248211A1
· Bender
· 2014
[cited by applicant]
US 20140271842A1
· Herbig et al.
· 2014
[cited by applicant]
US 20150050373A1
· Saklani et al.
· 2015
[cited by applicant]
US 20150057341A1
· Perry
· 2015
[cited by applicant]
US 20150126595A1
· Smith
· 2015
[cited by applicant]
US 20150126754A1
· Fernandez Cid et al.
· 2015
[cited by applicant]
US 20150132396A1
· Coulter et al.
· 2015
[cited by applicant]
US 20150181925A1
· Turner
· 2015
[cited by applicant]
US 20150273069A1
· Bjerregaard et al.
· 2015
[cited by applicant]
US 20160030436A1
· Kim et al.
· 2016
[cited by applicant]
US 20160355853A1
· Winnicki et al.
· 2016
[cited by applicant]
US 20180263913A1
· Lefler et al.
· 2018
[cited by applicant]
US 20190117778A1
· Leone-Bay et al.
· 2019
[cited by applicant]
US 20190336472A1
· Leone-Bay et al.
· 2019
[cited by applicant]
US 20200078332A1
· Leone-Bay et al.
· 2020
[cited by applicant]
US 20200101034A1
· Leone-Bay et al.
· 2020
[cited by applicant]
US 20200197521A1
· Leone-Bay et al.
· 2020
[cited by applicant]
US 20200254041A1
· Leone-Bay et al.
· 2020
[cited by applicant]
US 20200268821A1
· Leone-Bay et al.
· 2020
[cited by applicant]
CN 101439074A
· 2009
[cited by applicant]
EP 2286793A2
· 2011
[cited by applicant]
GB 2377633A
· 2003
[cited by applicant]
JP 2016509842A
· 2016
[cited by applicant]
WO WO199630036A1
· 1996
[cited by applicant]
WO WO9808490A1
· 1998
[cited by applicant]
WO WO0032200A1
· 2000
[cited by applicant]
WO WO2001019901A2
· 2001
[cited by applicant]
WO WO200172286A1
· 2001
[cited by applicant]
WO WO2003084518A2
· 2003
[cited by applicant]
WO WO2004026857A2
· 2004
[cited by applicant]
WO WO2004050011A2
· 2004
[cited by applicant]
WO WO2005123051A2
· 2005
[cited by applicant]
WO WO2005065661A2
· 2005
[cited by applicant]
WO WO2006043260A2
· 2006
[cited by applicant]
WO WO2006108692A2
· 2006
[cited by applicant]
WO WO2006134523A2
· 2006
[cited by applicant]
WO WO2007056242A1
· 2007
[cited by applicant]
WO WO2007112399A2
· 2007
[cited by applicant]
WO WO2008024408A2
· 2008
[cited by applicant]
WO WO2008033024A2
· 2008
[cited by applicant]
WO WO2008118414A1
· 2008
[cited by applicant]
WO WO2008122967A2
· 2008
[cited by applicant]
WO WO2009100245A1
· 2009
[cited by applicant]
WO WO2010127033A1
· 2010
[cited by applicant]
WO WO2012069591A1
· 2012
[cited by applicant]
WO WO2013045115A1
· 2013
[cited by applicant]
WO WO2013174854A1
· 2013
[cited by applicant]
WO WO2014046983A9
· 2014
[cited by applicant]
WO WO2014159688A1
· 2014
[cited by applicant]
WO WO2015118549A1
· 2015
[cited by applicant]
WO WO2015131269A1
· 2015
[cited by applicant]
WO WO2015198078A1
· 2015
[cited by applicant]
WO WO2016022936A1
· 2016
[cited by applicant]
WO WO2016138505A1
· 2016
[cited by applicant]
WO WO2016205923A1
· 2016
[cited by applicant]
WO WO2017185038A1
· 2017
[cited by examiner]
WO WO2018033927A1
· 2018
[cited by examiner]
WO WO2018102029A1
· 2018
[cited by applicant]
WO WO2018129097A1
· 2018
[cited by applicant]
WO WO2018175992
· 2018
[cited by applicant]
WO WO2019071211A1
· 2019
[cited by applicant]
WO WO2019071213A1
· 2019
[cited by applicant]
Wheless et al. 2019, CNS Drugs, 33: 593-604, “Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy” (Year: 2019).
[cited by examiner]
Badowski et al. Cancer Chemother Pharmacol. 2017, vol. 80, pp. 441-449, “A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic vari…
[cited by examiner]
MacCallum et al. European Journal of Internal Medicine, 2018, vol. 49, p. 12-19, “Practical considerations in medical cannabis administration and dosing”. (Year: 2018).
[cited by examiner]
Bittner et al. Pharmazie, 2012, vol. 67, pp. 233-241, “Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC)” (Year: 20…
[cited by examiner]
Office Action Dated Mar. 16, 2021 in Japanese Application No. 2019-506612, 5 pages.
[cited by applicant]
Katsuyama, et al., “Involvement of peripheral cannabinoid and opioid receptors in Beta-caryophyllene-induced antinociception,” Eur. J. Pain, vol. 17, No. 5, 2013, pp. 664-675.
[cited by applicant]
Kobayashi, et al., “Synthesis of Cannabidiols via Alkenylation of Cyclohexenyl Monoacetate,” J. Am. Chem. Soc., vol. 8, No. 13, 2006, pp. 2699-2702.
[cited by applicant]
Kremer, et al., “Pharmacokinetics, pharmacodynamics and tolerability of oral cromolyn sodium/SNAC capsules in healthy and allergic male subjects,” Br. J. Clin. Pharmacol., vol. 56, 2003, pp. 467-468.
[cited by applicant]
Lam, et al., “A Review on Medicinal Properties of Orientin,” Adv. Pharmacol. Sci., vol. 2016, 2016, 9 pages.
[cited by applicant]
Lastres-Becker, et al., “Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease,” J. Neurochem., vol. 84, No. 5, 2003 , pp. 1097-1109.
[cited by applicant]
Leone-Bay, et al., “Synthesis and evaluation of compounds that facilitate the gastrointestinal absorption of heparin,” J. Med. Chem., vol. 41, No. 7, 1998, pp. 1163-1171.
[cited by applicant]
Linck, et al., “Effects of inhaled Linalool in anxiety, social interaction and aggressive behavior in mice,” Phytomedicine, vol. 17, No. 8-9, 2002, pp. 679-683.
[cited by applicant]
Lorenzetti, et al., “Myrcene mimics the peripheral analgesic activity of lemongrass tea,” J. of Ethnopharmacology, vol. 34, No. 1, 1991, pp. 43-48.
[cited by applicant]
Lyman, et al., “Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis,” J. Neuroimmunol., vol. 23, No. 1, 1989, pp. 73-81.
[cited by applicant]
Martyn, et al., “Nabilone in the treatment of multiple sclerosis,” Lancet, vol. 345, No. 8949, 1995, p. 579.
[cited by applicant]
McCartney, et al., “Safety concerns over the use of intestinal permeation enhancers: A mini-review,” Tissue Barriers, vol. 4, No. 2, 2016, 14 pages.
[cited by applicant]
Mechoulam, et al., “A Total Synthesis of dl-delta-Tetrahydrocannabinol, the Active Constituent of Hashish,” J. Am. Chem. Soc., vol. 87, No. 14, 1965, pp. 3273-3275.
[cited by applicant]
Muller, et al., “Preparation and characterization of mucus-penetrating papain/poly(acrylic acid) nanoparticles for oral drug delivery applications,” Journal of Nanoparticle Research, vol. 15, 2012, pp. 1-13.
[cited by applicant]
Office Action Dated Oct. 1, 2020 in Mexican Application No. MX/a/2019/006439, 4 pages.
[cited by applicant]
Office Action Dated Aug. 11, 2020 in Mexican Application No. MX/a/2018/012913, 3 pages.
[cited by applicant]
Office Action Dated Sep. 22, 2020 in Mexican Application No. MX/a/2019/007968, 3 pages.
[cited by applicant]
Nissen, et al., “Characterization and antimicrobial activity of essential oils of industrial hemp varieties (
[cited by applicant]
Examination Report Dated Nov. 10, 2020 in New Zealand Application No. 747886, 5 pages.
[cited by applicant]
Examination Report Dated Nov. 23, 2020 in New Zealand Application No. 754983, 5 pages.
[cited by applicant]
Office Action Dated Oct. 29, 2020 for U.S. Appl. No. 16/805,356, 5 pages.
[cited by applicant]
Office Action Dated Oct. 3, 2019 for U.S. Appl. No. 16/094,802, 5 pages.
[cited by applicant]
Office Action Dated Mar. 26, 2021 in U.S. Appl. No. 16/465,984, 9 pages.
[cited by applicant]
Oh, et al., “Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers,” Clin. Pharmacol., vol. 9, 2017, pp. 9-17.
[cited by applicant]
Paula-Freire, et al., “Ocimum gratissimum Essential Oil and Its Isolated Compounds (Eugenol and Myrcene) Reduce Neuropathic Pain in Mice,” Planta Med., vol. 82, No. 3, 2016, pp. 211-216.
[cited by applicant]
PCT Invitation to Pay Additional Fees Dated Mar. 6, 2018 in PCT Application No. PCT/US2018/012261, 2 pages.
[cited by applicant]
PCT Invitation to Pay Additional Fees Dated Jun. 29, 2018 in PCT Application No. PCT/US2018/024188, 2 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability Dated Nov. 1, 2018 for PCT Application No. PCT/US2017/028953, 12 pages.
[cited by applicant]
Search Report and Written Opinion Dated Nov. 29, 2018 for International Application No. PCT/US2018/054733, 21 pages.
[cited by applicant]
Search Report and Written Opinion Dated Dec. 12, 2018 for International Application No. PCT/US2018/054728, 17 pages.
[cited by applicant]
Search Report and Written Opinion Dated Dec. 28, 2017 for International Application No. PCT/US2017/055547, 11 pages.
[cited by applicant]
Search Report and Written Opinion Dated Apr. 26, 2018 for International Application No. PCT/US2018/012261, 11 pages.
[cited by applicant]
Seach Report and Written Opinion Dated Jul. 21, 2017 for International Application No. PCT/US17/28953, 13 pages.
[cited by applicant]
Search Report and Written Opinion Dated Aug. 29, 2018 for International Application No. PCT/US2018/024188, 14 pages.
[cited by applicant]
Search Report and Written Opinion Dated Feb. 3, 2020 for International Application No. PCT/US2019/062281, 8 pages.
[cited by applicant]
Perry, et al., “In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes,” Journal of Pharmacy and Pharmacology, vol. 52, No. 7, 2010, pp. 895-902.
[cited by applicant]
Petrzilka, et al., “Synthese und Chiralitat des (−)-Cannabidiols Vorlaufige Mitteilung,” Helv. Chim. Acta, vol. 50, No. 2, 1967, pp. 719-723.
[cited by applicant]
PubChem, “Salcaprozate Sodium,” retrieved on Nov. 29, 2018 at <<https://pubchem.ncbi.nlm.nih.gov/compound/Salcaprozate sodium#/section=Information-Sources>>, Feb. 5, 2008, pp. 1-17.
[cited by applicant]
Rao, et al., “Effect of myrcene on nociception in mice,” J. Pharm. Pharmacol., vol. 42, No. 12, 1990, pp. 877-878.
[cited by applicant]
Resstel, et al., “5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats,” Br. J. Pharmacol., vol. 156, No. 1, 2009, pp. 181-18…
[cited by applicant]
Rice, et al., “Characterizing the Smell of Marijuana by Odor Impact of Volatile Compounds: An Application of Simultaneous Chemical and Sensory Analysis,” PloS One, vol. 10, No. 12, 2015, pp. 1-17.
[cited by applicant]
Robson, “Therapeutic aspects of cannabis and cannabinoids,” Br. J. Psychiatry, vol. 178, No. 2, 2001, pp. 107-115.
[cited by applicant]
Rothschild, et al., “Cannabis sativa: volatile compounds from pollen and entire male and female plants of two variants, Northern Lights and Hawaian Indica, ” Botanical Journal of the Linnean Society, vol. 147, No. 4, 20…
[cited by applicant]
Salgueiro, et al., “Anxiolytic Natural and Synthetic Flavonoid Ligands of the Central Benzodiazepine Receptor Have No Effect on Memory Tasks in Rats,” Pharmacol. Biochem. Behav., vol. 58, No. 4, 1997, pp. 887-891.
[cited by applicant]
Schaeffer, “5 Supplements That Can Treat Migraines,” retrieved at <<https://www.healthline.com/health/migraine/migraine-vitamins#1>>, Healthline, Mar. 24, 2016, 11 pages.
[cited by applicant]
European Office Action mailed Oct. 20, 2022 for European Patent Application No. 21175803.2, a foreign counterpart to U.S. Pat. No. 10,588,974, 5 pages.
[cited by applicant]
Extended European Search Report mailed Nov. 14, 2022, for European Patent Application No. 19886986.9, 8 pages.
[cited by applicant]
Final Office Action Dated Jul. 19, 2022 in U.S. Appl. No. 16/753,721, 15 pages.
[cited by applicant]
Office Action Dated Mar. 8, 2022 in Japanese Application No. 2019-536222, 4 pages.
[cited by applicant]
Office Action Dated Mar. 9, 2022 in Chinese Application No. 201780075150.0, 9 pages.
[cited by applicant]
“Cannabis (Marijuana) and Cannabinoids: What You Need to Know.” National Center for Complementary and Integrative Health, U.S. Department of Health and Human Services, 2019, https://www.nccih.nih.gov/health/cannabis-mar…
[cited by applicant]
Office Action Dated Oct. 19, 2021 in Japanese Application No. 2019-536222, 4 pages.
[cited by applicant]
Office Action Dated Oct. 20, 2021 for Mexican Application No. MX/a/2019/007968, 4 pages.
[cited by applicant]
Office Action Dated Nov. 29, 2021 in U.S. Appl. No. 16/753,721, 10 pages.
[cited by applicant]
Office Action Dated Dec. 7, 2021 in U.S. Appl. No. 16/474,480, 14 pages.
[cited by applicant]
Search Report Dated Nov. 25, 2021 in European Application No. 21175803.2, 6 pages.
[cited by applicant]
Baker and Pryce, “The therapeutic potential of cannabis in multiple sclerosis,” Expert Opin. Investig. Drugs, vol. 12, No. 4, 2003, pp. 561-567.
[cited by applicant]
Basavarajappa and Hungund, “Role of the endocannabinoid system in the development of tolerance to alcohol,” Alcohol Alcohol., vol. 40, No. 1, 2005, pp. 15-24.
[cited by applicant]
Burstein and Zurier “Cannabinoids, endocannabinoids, and related analogs in inflammation,” AAPS J., vol. 11, No. 1, 2009, pp. 109-119.
[cited by applicant]
Burstein, “Cannabidiol (CBD) and its analogs: a review of their effects on inflammation,” Bioorg. Med. Chem., vol. 23, 2015, pp. 1377-1385.
[cited by applicant]
Choudhary, et al., “Development and characterization of an atorvastatin solid dispersion formula using skimmed milk for improved oral bioavailability,” Acta Pharmaceutica Sinica B, vol. 2, No. 4, 2012, pp. 421-428.
[cited by applicant]
Office Action Dated Jun. 14, 2021 in European Application No. 17875117.2, 5 pages.
[cited by applicant]
Extended European Search Report Dated Jul. 29, 2021 for European Application No. 18865203.6, 15 pages.
[cited by applicant]
Gaffal, et al., “Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis Independent of CB1 and CB2 receptors,” Allergy, vol. 68, No. 8, 2013, pp. 994-1000.
[cited by applicant]
Heckelman, et al, The Merck Index: an encyclopedia of chemicals, drugs, and biologicals, (No. 615.11 MER), p. 146.
[cited by applicant]
Huestis, “Human Cannabinoid Pharmacokinetics,” Chem. Biodivers., vol. 4, No. 8, 2007, pp. 1770-1804.
[cited by applicant]
Office Action Dated Sep. 14, 2021 in Japanese Application No. 2019-529537, 7 pages.
[cited by applicant]
Kim & Yoon, “Rapid screening for acidic non-steroidal anti-inflammatory drugs in urine by gas chromatography-mass spectrometry in the selected-ion monitoring mode,” J. Chromatogr. B. Biomed Appl., vol. 682, No. 1, 1996,…
[cited by applicant]
Office Action Dated Sep. 30, 2021 in Korean Application No. 10-2018-7033084, 10 pages.
[cited by applicant]
Maher, et al., “Intestinal permeation enhancers for oral peptide delivery,” Adv. Drug Del. Rev., vol. 106, 2016, pp. 277-319.
[cited by applicant]
O'Connell and Bov-Matar, “Long term marijuana users seeking medical cannabis in California (2001-2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants,” Harm Reduct. J.,…
[cited by applicant]
Final Office Action Dated Jul. 27, 2021 in U.S. Appl. No. 16/474,480, 15 pages.
[cited by applicant]
Ohlsson, et al. “Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking,” Clin. Pharmacol. Ther., vol. 28, No. 3, 1980, pp. 409-416.
[cited by applicant]
Peana, et al., “Anti-inflammatory activity of linalool and linalyl acetate constituents of essential oils,” Phytomedicine, vol. 9, 2002, pp. 721-726.
[cited by applicant]
Peana, et al., “Linalool produces antinociception in two experimental models of pain,” Euro. Jour. Pharm., vol. 460, No. 1, 2003, pp. 37-41.
[cited by applicant]
Perez-Reyes, et al., “Pharmacology of orally administered delta-9-tetrahydrocannabinol,” Clin Pharmacol Ther., vol. 14, No. 1, 1973, pp. 48-55.
[cited by applicant]
Raman, et al., “Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid,” Amyotroph Lateral Scler. Other Motor Neuron Disord., vol. 5, No., 1, 2004, pp. 33-39.
[cited by applicant]
Russo, “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects,” BJP, vol. 163, 2011, pp. 1344-1364.
[cited by applicant]
Russo, et al., “A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol,” Med. Hypotheses, vol. 66, No. 2, 2006, pp. 234-246.
[cited by applicant]
Shoba, et al. “Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers,” Planta Med, vol. 64, No. 4, 1998, pp. 353-356.
[cited by applicant]
Zanelati, et al., “Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors,” Br. J. Pharmacol., vol. 159, No. 1, 2010, pp. 122-128.
[cited by applicant]
Shohami, et al., “Endocannabinoids and traumatic brain injury,” Br. J. Pharmacol., vol. 163, No. 7, 2011, pp. 1402-1410.
[cited by applicant]
Sieradzan, et al., “Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study,” Neurology, vol. 57, No. 11, 2001, pp. 2108-2111.
[cited by applicant]
Souto-Maior, et al., “Anxiolytic-like effects of inhaled linalool oxide in experimental mouse anxiety models,” Pharmacol. Biochem. Behav., vol. 100, No. 2, 2011, pp. 259-263.
[cited by applicant]
Syed, et al., “Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex) A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis,” Drugs, vol. 74, No. 5, 2014, pp. 563-578.
[cited by applicant]
Tarapore, et al., “The dietary terpene lupeol targets colorectal cancer cells with constitutively active Wnt/beta-catenin signaling,” Molecular Nutrition and Food Research, vol. 57, No. 11, 2013, pp. 1950-1958.
[cited by applicant]
Tashkin, et al., “Effects of smoked marijuana in experimentally induced asthma,” Am. Rev. Respir. Dis., vol. 112, No. 3, 1975, pp. 377-386.
[cited by applicant]
Victorio, et al., “Flavonoid extraction from Alpinia zerumbet (Pers.) Burttet Smith leaves using different techniques and solvents,” Ecl. Quinn., vol. 34, No. 1, 2009, pp. 19-24.
[cited by applicant]
Vuolo, et al., “Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma,” Mediators of Inflammation, vol. 2015, No. 538670, 5 pages.
[cited by applicant]
Walsh, et al., “Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion,” Br. J. Pharmacol., vol. 160, No. 5, 2010, pp. 1234-1242.
[cited by applicant]
Wheless, et al., “Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients With Treatment-Resistant Epilepsy,” CNS Drugs, vol. 33, No. 6, 2019, pp. 593-604.
[cited by applicant]
Yadav, et al., “Effect of Cyclodextrin Complexation of Curcumin on its Solubility and Antiangiogenic and Anti-inflammatory Activity in Rat Colitis Model,” AAPS Pharm. Sci. Tech. vol. 10, No. 3, 2009, 11 pages.
[cited by applicant]
Abramovici, “Information for Health Care Providers Cannabis and the Cannabinoids,” Health Canada, 2013, 158 pages.
[cited by applicant]
Aungst, et al., “Absorption Enhancers: Applications and Advances”, The AAPS Journal, vol. 14, No. 1, 2012, 9 pages.
[cited by applicant]
Bab, et al., “Cannabinoids and the skeleton: from marijuana to reversal of bone loss,” Ann. Med., vol. 41, No. 8, 2009, pp. 560-567.
[cited by applicant]
Babaee, et al., “Antioxidant capacity of calendula officinalis flowers extract and prevention of radiation induced propharyngeal mucositis in patients with head and neck cancers: a randomized controlled clinical study,”…
[cited by applicant]
Bahi, et al., “Beta—Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice,” Physiol. Behav., vol. 135, 2014, pp. 119-124.
[cited by applicant]
Barrett, et al., “Cannflavin A and B, prenylated flavones from
[cited by applicant]
Baughman, et al., “Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans,” Circulation, vol. 98, No. 16, 1998, pp. 1610-1615.
[cited by applicant]
Beal, et al., “Dronabinol as a treatment for anorexia associated with weight loss in patients with Aids,” J. Pain. Symptom Manage., vol. 10, No. 2, 1995, pp. 89-97.
[cited by applicant]
Binet, et al., “Pharmacodynamic properties (sedative action and spasmolytic action) of several aliphatic terpene alcohols,” Ann. Pharm. Fr., vol. 30, No. 9, 1972, pp. 611-616.
[cited by applicant]
Biro, et al., “The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities,” Trends Pharmacol. Sci., vol. 30, No. 8, 2009, pp. 411-420.
[cited by applicant]
Bittner, et al., “Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC)”, Pharmazie, vol. 67, 2012, pp. 233-241.
[cited by applicant]
Brenneisen, “Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents,” Humana Press Inc., Totowa, New Jersey, 2007, pp. 17-49.
[cited by applicant]
Calderon-Montano, et al., “A Review on the Dietary Flavonoid Kaempferol,” Mini. Rev. Med. Chem., vol. 11, No. 4, 2011, pp. 298-344.
[cited by applicant]
Campos, et al., “Cannabidiol, neuroprotection and neuropsychiatric disorders,” Pharmacol. Res., vol. 112, 2016, pp. 119-127.
[cited by applicant]
Cardi, et al., “Superiority of Laparoscopy Compared to Ultrasonography in Diagnosis of Widespread Liver Diseases,” Dig. Dis. Sci., vol. 42, No. 3, 1997, pp. 546-547.
[cited by applicant]
Castelli, et al., “Comparing the Efficacy and Tolerability of a New Daily Oral Vitamin B12 Formulation and Intermittent Intramuscular Vitamin B12 in Normalizing Low Cobalamin Levels: A Randomized, Open-Label, Parallel-G…
[cited by applicant]
Castelli, et al., “Pharmacokinetics of Oral Cyanocobalamin Formulated with Sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC): An Open-Label, Randomized, Single-DOSE, Parallel-Group Study in Healthy Male Subjects,” C…
[cited by applicant]
Office Action Dated Oct. 30, 2020 in Chilean Application No. 201901471, 15 pages.
[cited by applicant]
Office Action Dated Jul. 31, 2020 in Chilean Application No. 201802997, 11 pages.
[cited by applicant]
Office Action Dated Sep. 14, 2020 in Chilean Application No. 201901832, 12 pages.
[cited by applicant]
Office Action Dated Apr. 20, 2021 in Chinese Application No. 201780024997.6, 6 pages.
[cited by applicant]
Office Action Dated Sep. 2, 2020 in Chinese Application No. 201780024997.6, 9 pages.
[cited by applicant]
Office Action Dated Dec. 9, 2020 in Colombian Application No. NC2018/0011299, 11 pages.
[cited by applicant]
Office Action Dated Apr. 30, 2020 in Colombian Patent Application No. NC2018/0011299, 8 pages.
[cited by applicant]
De Vries, et al., “Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats,” Psychopharmacology [Berl], vol. 168, No. 1-2, 2003, pp. 164-169.
[cited by applicant]
Ding, et al., “Oral Absorption Enhancement of Cromolyn Sodium Through Noncovalent Complexation,” Pharmaceutical Research, vol. 21, No. 12, 2004, pp. 2196-2206.
[cited by applicant]
Office Action Dated Nov. 12, 2019 in Eurasian Application No. 201892396, 6 pages.
[cited by applicant]
Office Action Dated Sep. 15, 2020 in European Application No. 17786760.3, 4 pages.
[cited by applicant]
Partial Search Report Dated Apr. 28, 2021 in European Application No. 18865203.6, 16 pages.
[cited by applicant]
Extended European Search Report Dated Jun. 15, 2020 in European Patent Application No. 17875177.2, 7 pages.
[cited by applicant]
Extended European Search Report Dated Oct. 17, 2019 for European Patent Application No. 17786760.3, 7 pages.
[cited by applicant]
Extended European Search Report Dated Nov. 27, 2020 in European Application No. 18770819.3, 9 pages.
[cited by applicant]
Extended European Search Report Dated Jul. 9, 2020 in European Application No. 18736204.1, 10 pages.
[cited by applicant]
Epps, et al., “Synergistic Endo- and Exo-Interactions Between Blueberry Phenolic Compounds, Grape Variety Fractions, Chocolate Covered Strawberries, and Fruit Smoothies,” J. of Food Res., vol. 2, No. 6, 2013, pp. 33-47.
[cited by applicant]
Eubanks, et al., “A molecular link between the active component of marijuana and Alzheimer's disease pathology,” Mol. Pharm., vol. 3, No. 6, 2006, pp. 773-777.
[cited by applicant]
Falk, et al., “Uptake, distribution and elimination of alpha-pinene in man after exposure by inhalation,” Scand. J. Work Environ. Health, vol. 16, No. 5, 1990, pp. 372-378.
[cited by applicant]
Florence, “The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual,” Pharm. Res., vol. 14, No. 3, 1997, pp. 259-266.
[cited by applicant]
Gertsch, et al., “Beta-caryophyllene is a dietary cannabinoid,” PNAS, vol. 105, No. 26, 2008, pp. 9099-9104.
[cited by applicant]
Gil, et al., “Comparative study of different essential oils of Bupleurum gibraltaricum Lamarck,” Pharmazie, vol. 44, No. 4, 1989, pp. 284-287.
[cited by applicant]
Grivennikov et al., “Immunity, Inflammation, and Cancer”, Cell, vol. 140, No. 6, 2010, pp. 883-899.
[cited by applicant]
Grotenhermen, et al., “The Therapeutic Potential of Cannabis and Cannabinoids,” Dtsch Arztebl Int., vol. 109, No. 29-30, 2012, pp. 495-501.
[cited by applicant]
Guimaraes-Santos, et al., “Copaiba Oil-Resin Treatment Is Neuroprotective and Reduces Neutrophil Recruitment and Microglia Activation after Motor Cortex Excitotoxic Injury,” J. Evid. Based Complementary Altern. Med., vo…
[cited by applicant]
Guindon and Hohmann, “The endocannabinoid system and cancer: therapeutic implication,” Br. J. Pharmacol., vol. 163, No. 7, 2011, pp. 1447-1463.
[cited by applicant]
Guzman, “Cannabinoids: Potential Anticancer Agents,” Nat. Rev. Cancer, vol. 3, 2003, pp. 745-755.
[cited by applicant]
Hess, et al., “Investigation of the Enhancing Mechanism of Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect of the Intestinal Permeability of Polar Molecules Utilizing a Voltage Clamp Method”, Departement of Pharmac…
[cited by applicant]
Holdcroft, et al., “Clinical Trial Experience with Cannabinoids,” Pharm. Sci., vol. 3, 1997, pp. 546-550.
[cited by applicant]
Office Action Dated Dec. 31, 2020 in Israel Application No. 262505, 4 pages.
[cited by applicant]